Last updated: 2026-09-05 09:31:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Unicycive Therapeutics, Inc. (UNCY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.15, with a market capitalisation of $144.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.71 to $8.74. This page covers its latest market performance, valuation, price trends and company information.
$144.57M | |
$5.24 | |
$87.30 | |
$2.02 | |
$5.30 | |
424.52K | |
-- | |
-- | |
$8.74 | |
$3.71 | |
-- | |
-- |
Unicycive Therapeutics, Inc. (UNCY) last closed at $5.30 as of 2026-09-04 23:36:00, unchanged from the previous close of $5.30.
During the latest regular trading session, UNCY traded between $2.02 and $87.30, with a volume of 424.52K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Unicycive Therapeutics, Inc. (UNCY) moved from $5.27 to $5.15, representing a decline of 2.20% ($0.12).
The stock traded between $5.13 and $5.24 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 616.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.7%
UNCY is currently trading at $5.15, placing it 28.7% of the way from its 52-week low of $3.71 to its 52-week high of $8.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Unicycive Therapeutics, Inc. (UNCY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.